Cube Labs: placement of 250,000 shares successfully closed ahead of schedule for a value of 500,000 euros
Rome, July 27, 2023 – Cube Labs S.p.A. (“Cube Labs” or “Company”) – an Italian venture builder in the healthcare technology sector and listed on the Euronext Growth Milan market, Professional Segment – announces the successful conclusion of the placement (“Placement”) aimed at qualified investors for a maximum of 250,000 shares (“New Shares”), with no nominal value, enjoying regular rights, and having the same rights as the currently circulating shares, as resolved by the Board of Directors on July 24, 2023.
The Placement was closed ahead of the date determined by the Company’s Board of Directors (July 28, 2023) with the subscription of the maximum number of New Shares placed.
As part of the Placement, all the New Shares were subscribed at a price of EUR 2.00 per share (including EUR 0.03 allocated to share capital and EUR 1.97 as a share premium), for a total value of EUR 500,000.00, by a leading European institutional investor.
Following the operation, Cube Labs’ share capital will amount to EUR 576,750.00, divided into 17,302,500 ordinary shares with no indication of the nominal value, and the Company’s float will reach 13.31%.
“We are extremely pleased to have received the trust of a leading European institutional investor in a volatile and complex market context,” says Filippo Surace, CEO, and founder of Cube Labs. “Concluding the placement operation ahead of schedule and with success is further confirmation of the market’s interest in our business model. Thanks to this operation, in addition to strengthening our equity, we will have greater resources to continue our growth path through expanding our portfolio of investments and developing innovative startups that are already present internationally.”
This press release is available on the company’s website www.cube-labs.com in the Investor Relations/Press Releases section.
The official text is the Italian version of the document. Any discrepancies or differences arisen in the translation are not binding and have no legal effect. In case of any dispute on the contents, the Italian original version shall always prevail.
Cube Labs
Cube Labs is an Italian venture builder in the healthcare technology sector created to bridge the gap between excellent academic science and the commercial Life Science market. Cube Labs creates new companies based on promising R&D activities and promotes innovation to transform pioneering science into healthcare solutions. Through its international network, Cube Labs collaborates with innovation stakeholders to transform outcomes for patients and accelerate the global transition to optimal health. Cube Labs S.p.A. is listed on Euronext Growth Milan, Professional Segment. For further information, please visit the website: www.cube-labs.com.
Cube Labs
Global Media Contact
Isil Guney
Tel: +90 5325027243
E-mail: i.guney@cube-labs.com
MIT SIM
Euronext Growth Advisor
E-mail: francesca.martino@mitsim.it
Tel.: +39 02 30561270
Investor Relations
Vincenza Colucci
E-mail: vincenza.colucci@cdr-communication.it
Marika Martinciglio
E-mail: marika.martinciglio@cdr-communication.it
Ufficio Stampa Italia di Cube Labs
Matteo Steinbach
Cell. +393461063989
E-mail: matteo.steinbach@secnewgate.it
Federico Ziglioli
Cell. +393331225959
E-mail: federico.ziglioli@secnewgate.it